A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures

PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Specific DNA a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Precis Oncol
Main Authors: Diossy, Miklos, Sztupinszki, Zsofia, Borcsok, Judit, Krzystanek, Marcin, Tisza, Viktoria, Spisak, Sandor, Rusz, Orsolya, Timar, Jozsef, Csabai, István, Fillinger, Janos, Moldvay, Judit, Pedersen, Anders Gorm, Szuts, David, Szallasi, Zoltan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8213828/
https://ncbi.nlm.nih.gov/pubmed/34145376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00199-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados